« Previous article
Lab Innovations Show...

Microbiome Therapeutics Innovation Group (MTIG) Forms


The Microbiome Therapeutics Innovation Group (MTIG) have formed a coalition which seeks to nurture innovation in microbiome therapeutics and microbiome-based products to address unmet medical needs and bring life-saving treatments to patients. The founding MTIG Board of Directors is comprised of Thomas J. DesRosier, Chairman of the MTIG Board and Executive Vice President, Chief Legal Officer and Secretary of Seres Therapeutics, Lee Jones, MTIG Secretary and Founder, President and Chief Executive Officer of Rebiotix Inc., and Bernat Olle, Co-founder and Chief Executive Officer of Vedanta Biosciences.

"The MTIG member companies are excited to work together to advance policy and regulatory solutions that support and sustain the development of safe, effective, microbiome therapeutics," said Chairman DesRosier. "The emerging microbiome arena is a new frontier of medical innovation and holds promise for a variety of chronic diseases and some infections. We look forward to engaging with policymakers, government agencies, clinicians and patients on the role of the microbiome in human health, and the potential opportunities that novel microbiome products create for the field of medicine and patients in need."

All pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG.

If you are interested in learning more about becoming a member, go to microbiometig.org/membership


      

Tags:

Date Published: 16th August 2018

Source article link: Microbiome Therapeutics Innovation Group (MTIG)


View full company details